Review explores antibody therapies for relapsed acute myeloid leukemia

Patients with acute myeloid leukemia who have relapsed face a difficult path. Their disease returns after initial treatment, and options are often limited. This review examines a new class of treatments called antibody-based therapies. These include unconjugated monoclonal antibodies, antibody-drug conjugates, and bispecific T cell engagers. The authors compared these modern tools against traditional cytotoxic regimens, which are the standard chemotherapy approaches used for years. The goal was to understand how these newer methods might change outcomes for people facing a second or third chance at survival. The review focused on three main areas: how well the drugs worked, how long the benefit lasted, and the safety profile for patients. While the study did not report specific numbers or exact results, it provided a broad look at the potential of these therapies. The authors noted that the evidence comes from a narrative review rather than a single large trial. This means the findings represent a collection of existing knowledge rather than new data from one specific experiment. Readers should understand that without specific numbers or a defined sample size, the certainty of the results is lower than a direct trial. Still, the review highlights the growing interest in these targeted approaches for a group of patients who need every possible option.